Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/2/2024 | $17.00 | Overweight → Neutral | Analyst |
| 11/13/2024 | $26.00 → $19.00 | Buy → Hold | Truist |
| 9/19/2024 | Mkt Outperform → Mkt Perform | JMP Securities | |
| 8/7/2024 | $37.00 → $24.00 | Buy → Hold | Canaccord Genuity |
| 8/7/2024 | $31.00 → $25.00 | Outperform → Market Perform | Leerink Partners |
| 8/7/2024 | Buy → Neutral | BTIG Research | |
| 7/16/2024 | $36.00 | Mkt Outperform | JMP Securities |
| 5/10/2024 | Overweight → Sector Weight | KeyBanc Capital Markets |
4 - Progyny, Inc. (0001551306) (Issuer)
4 - Progyny, Inc. (0001551306) (Issuer)
4 - Progyny, Inc. (0001551306) (Issuer)
Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (NASDAQ:SIBN), a medical device company solving musculoskeletal disorders of the sacropelvic anatomy. She was previously the Chief Financial Officer and Chief Operating Officer of the company. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with
NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a transformative fertility, family building, and women's health benefits solution, today announced the acquisition of BenefitBump, a comprehensive parental leave benefits navigation program for new and growing families. This addition enhances Progyny's fertility and family building offering, extending the company's ability to further serve the needs of families on their journey from pregnancy to early childhood and beyond. With 90% of parents seeking greater support to manage responsibilities at work and home, Progyny's enhanced suite of solutions aims to reduce member stress, improve recruitment, return-to-work and
NEW YORK, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a transformative fertility, family building and women's health benefits solution, today announced the appointment of 30-year healthcare industry veteran Debra Morris to its board of directors, effective January 16, 2025. Debra Morris currently serves as President of AccessHope, a company changing the way leading-edge cancer expertise is delivered. Previously she served as EVP and CFO of Apria Healthcare where she demonstrated her ability to navigate complex industry challenges, drive operational excellence, and deliver value to stakeholders. With her extensive board service and proven leadership in handling periods o
S-8 - Progyny, Inc. (0001551306) (Filer)
10-K - Progyny, Inc. (0001551306) (Filer)
8-K/A - Progyny, Inc. (0001551306) (Filer)
4 - Progyny, Inc. (0001551306) (Issuer)
4 - Progyny, Inc. (0001551306) (Issuer)
Reports Quarterly Revenue of $298.4 Million, Reflecting 10.6% GrowthGenerated $52.2 Million of Quarterly Operating Cash FlowIssues Financial Guidance for 2025, Reflecting Tenth Consecutive Year of Revenue Growth NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a transformative fertility, family building and women's health benefits solution, today announced its financial results for the three- and twelve-month periods ended December 31, 2024 ("the fourth quarter of 2024" and "the full year", respectively) as compared to the three- and twelve-month periods ended December 31, 2023 ("the fourth quarter of 2023" and "the prior year period",
NEW YORK, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a transformative fertility, family building, and women's health benefits solution, will report its financial results for the quarterly period and full year ended December 31, 2024, after the close of the market on Thursday, February 27, 2025. The company will host a conference call at 4:45 p.m. Eastern Time (1:45 p.m. Pacific Time) and issue a press release regarding its financial results prior to the start of the call. Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the passcode 265484. International participants may access the call by dialing 1.973.41
Sales Season Yields Over 80 New Clients, 1.1 Million New Covered LivesSelected by a Leading National Health Plan and a Regional Health Plan as Their Preferred Partner1.5 Million Lives Adopt Newest Services in Maternity and/or Menopause Programs in 2025 NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a transformative fertility, family building and women's health benefits solution, today announced its financial results for the three-month period ended September 30, 2024 ("the third quarter of 2024") as compared to the three-month period ended September 30, 2023 ("the third quarter of 2023" or "the prior year period"). "The utilization r
SC 13G/A - Progyny, Inc. (0001551306) (Subject)
SC 13G/A - Progyny, Inc. (0001551306) (Subject)
SC 13G/A - Progyny, Inc. (0001551306) (Subject)
NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a transformative fertility, family building, and women's health benefits solution, today announced it expects to participate in several upcoming investor conferences. Progyny executives will participate in a fireside chat at the Leerink Partners Global Healthcare Conference in Miami, FL on Monday, March 10, 2025, at 11:20 a.m. Eastern Time. The executives will then be participating in meetings at the Barclays 27th Annual Global Healthcare Conference in Miami, FL on Tuesday, March 11, 2025. Pete Anevski, Chief Executive Officer, will also participate in a virtual fireside chat at the KeyBanc Capital Markets Healthcar
Reports Quarterly Revenue of $298.4 Million, Reflecting 10.6% GrowthGenerated $52.2 Million of Quarterly Operating Cash FlowIssues Financial Guidance for 2025, Reflecting Tenth Consecutive Year of Revenue Growth NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a transformative fertility, family building and women's health benefits solution, today announced its financial results for the three- and twelve-month periods ended December 31, 2024 ("the fourth quarter of 2024" and "the full year", respectively) as compared to the three- and twelve-month periods ended December 31, 2023 ("the fourth quarter of 2023" and "the prior year period",
Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (NASDAQ:SIBN), a medical device company solving musculoskeletal disorders of the sacropelvic anatomy. She was previously the Chief Financial Officer and Chief Operating Officer of the company. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with
Analyst downgraded Progyny from Overweight to Neutral and set a new price target of $17.00
Truist downgraded Progyny from Buy to Hold and set a new price target of $19.00 from $26.00 previously
JMP Securities downgraded Progyny from Mkt Outperform to Mkt Perform